Actinogen Medical Ltd (ASX: ACW) has announced a significant milestone in the development of its lead candidate, Xanamem®(emestedastat), with the 100th participant now enrolled in its pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial. This event formally triggers the timeline for an independent interim analysis of safety and efficacy, bringing the company one step closer to potentially introducing a novel oral therapy for Alzheimer’s disease (AD).